Murdoch University Research Repository

Welcome to the Murdoch University Research Repository

The Murdoch University Research Repository is an open access digital collection of research
created by Murdoch University staff, researchers and postgraduate students.

Learn more

Treatment patterns of patients with multiple sclerosis in Guangzhou, China

Li, R., Wang, J., Li, J., Wang, Y., Wu, H., Fan, P., Lau, A.Y., Kermode, A.G. and Qiu, W. (2020) Treatment patterns of patients with multiple sclerosis in Guangzhou, China. Neurology Asia, 25 (2). pp. 173-182.

[img]
Preview
PDF - Published Version
Download (531kB) | Preview
Free to read: http://www.neurology-asia.org/articles/neuroasia-2...
*No subscription required

Abstract

Background & Objective: Disease-modifying treatments (DMTs) for multiple sclerosis (MS) are widely used in Western countries. In China, however, the current treatment patterns of MS patients are not well characterized. This is to explore the gap between the current treatments in Guangzhou, Southern China and those given in Western countries. Methods: We performed a survey of MS patients at department of neurology, a tertiary MS referral centre in Guangzhou, concerning treatments of MS in Southern China. The clinical data in patients were collected. The initial treatment, drug withdrawal or switching profile, and therapeutic effect of existing treatments in MS patients were analyzed. Results: The ratio of MS patients who receive DMTs in Guangzhou China is extremely low. Among the 178 patients studied, only 28.09% received initial treatment with DMTs. MS patients who receive initial treatment with first-line DMTs have higher drug withdrawal rates (32.6%) and drug switching rates (30.43%) than those of western populations. The main reasons for withdrawal of first-line DMTs were doctor’s advice (maintenance of remission)(40.00%), economic burden(20.00%), and no channels to buy drugs(13.33%). In MS patients initially treated with first-line DMTs who switched to other drugs, a gap between treatments was common (8/14; 57.14%). There were 18 patients with highly active MS receiving treatment with rituximab. Annual relapse rate after treatment significantly decreased than that before treatment (0.74 vs. 1.50 , P < 0.001). Conclusions: DMTs for MS in Guangzhou, Southern China appear to lag behind those in Western countries. Much work is needed to improve drug accessibility and affordability of DMTs in China. Rituximab is an option for highly active MS in limited medical-resource countries.

Item Type: Journal Article
Murdoch Affiliation: Institute for Immunology and Infectious Diseases
Publisher: ASEAN Neurological Association
Copyright: © 2020 ASEAN Neurological Association.
Other Information: Appears in: PACTRIMS 2019, Singapore, 13 - 15 NOV 2019.
URI: http://researchrepository.murdoch.edu.au/id/eprint/57394
Item Control Page Item Control Page

Downloads

Downloads per month over past year